Start the conversation
After doubling in price in just three months, shares of TrovaGene Inc. (Nasdaq: TROV) - the San Diego-based "liquid-biopsy" play we first recommended back on March 11 - have sold off sharply in the past week.
That's not a surprise.
In our initial report, we classified TrovaGene as an ultra-high-risk stock, said to expect a volatile run, and recommended investors be willing to hold the shares for at least two years to ride out the big swings that almost always accompany a high-risk/high-return-potential stock like this one.
This is premium content for Private Briefing subscribers only.